6/24 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Wang et al., Front. Bioeng. Biotechnol., doi:10.3389/fbioe.2021.646184 (Peer Reviewed) Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study
Prophylaxis RCT in China with 98 healthcare workes in close contact with COVID-19 patients treated with Bactoblis oropharyngeal probiotic containing S. thermophilus ENT-K12, and 95 control patients, showing lower incidence of respiratory infections with treatment (none were confirmed COVID-19, details of testing are not provided).
Wang et al., 6/24/2021, peer-reviewed, 13 authors.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC.